Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry
نویسندگان
چکیده
AIM To compare and contrast the characteristics and clinical outcomes of patients who have received daptomycin as outpatients and inpatients. METHODS The Cubicin Outcomes Registry and Experience (CORE) is a retrospective chart review of patients who have received daptomycin in participating institutions. Patients treated in 2005 were included in this analysis. Demographic characteristics and clinical outcomes (success = cured + improved) were compared among patients who received outpatient parenteral antibiotic therapy (OPAT) and patients who had received inpatient parenteral antibiotic therapy (IPAT). RESULTS Of 1172 patients reported by 52 CORE 2005 participating institutions/investigators, 949 (81.0%) patients were evaluable: 539 (56.8%) received OPAT (OPAT patients), and 410 (43.2%) received only IPAT (IPAT patients). Of the 539 OPAT patients, 273 (50.6%) also received some IPAT, usually preceding OPAT therapy. Successful outcomes [no. of successes/(no. of successes + no. of failures)] for OPAT patients vs. IPAT patients were 94.6% and 86.3% respectively (chi-square test, p < 0.001). OPAT patients were younger, had fewer underlying diseases, were clinically stable, and had fewer adverse events than IPAT patients. CONCLUSIONS Outpatient parenteral antibiotic therapy use was common (539/949 or 56.8%) among patients in CORE 2005. Clinical outcomes among OPAT patients appeared at least as good as or better than IPAT patients. Better outcomes among OPAT patients were most likely because of patient selection for OPAT. Additional studies should focus on clinical characteristics of patients who would be ideal candidates for daptomycin OPAT.
منابع مشابه
Comment on: Developments in outpatient parenteral antimicrobial therapy (OPAT) for Gram-positive infections in Europe, and the potential impact of daptomycin.
Parenteral antimicrobial therapy is traditionally offered in the inpatient setting in many parts of the world. In the USA, the past three decades have seen an unprecedented increase in the delivery of these therapies in the non-inpatient setting, and outpatient parenteral antibiotic therapy (OPAT) is now an established standard of care in North America. However, the uptake of OPAT within Europe...
متن کاملEconomic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin
BACKGROUND Previous economic analyses evaluating treatment of methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft-tissue infections (cSSTI) failed to include all direct treatment costs such as outpatient parenteral antibiotic therapy (OPAT). Our objective was to develop an economic model from a US payer perspective that includes all direct inpatient and outpatient costs...
متن کاملOutpatient parenteral antimicrobial therapy for infective endocarditis in patients over 80 years.
OBJECTIVE The incidence of infective endocarditis is progressively increasing, especially in elderly patients. Outpatient parenteral antibiotic therapy (OPAT) is being an excellent alternative for treatment, but advanced age is one of the relative contraindications. The aim of this study is to compare the characteristics and prognosis of patients less or more than 80 years, treated with OPAT. ...
متن کاملComplicated skin and soft tissue infections: literature review of evidence for and experience with daptomycin
Skin and soft tissue infections (SSTIs) are the second most common infection encountered in hospitals. Management decisions have become increasingly complex due to the prevalence of resistant pathogens, the wide array of licensed antimicrobials and the availability of potent oral agents and of out-patient parenteral antibiotic therapy. Daptomycin is one of the newer therapeutic agents licensed ...
متن کاملClinical experience with daptomycin in Europe: the first 2.5 years
OBJECTIVES To describe the patient populations and infections being treated with daptomycin, as well as the efficacy and safety outcomes. PATIENTS AND METHODS Data from the European Cubicin Outcomes Registry and Experience (EU-CORESM), retrospectively collected at 118 institutions between January 2006 and August 2008, were analysed. RESULTS Daptomycin treatment was documented in 1127 patien...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- International Journal of Clinical Practice
دوره 62 شماره
صفحات -
تاریخ انتشار 2008